FDA Approves Sonidegib for Locally Advanced Basal Cell Carcinoma
The FDA has approved sonidegib (Odomzo) for the treatment of basal cell carcinoma that has recurred following surgery or radiotherapy.
All articles by Ali McBride, PharmD, MS, BCPS
Rectal Cancer Outcomes Predicted by Pre-Operative MRI of Margins
Overall and disease-free survival, local recurrence can be predicted by MRI assessment of circumferential resection margin before surgery for rectal cancer.
Chemotherapy Drug Shortages: The Impact on Oncology Practice
Shortages of chemotherapy drugs can cause treatment delays for patients, and in some cases, prevent them from receiving treatment at all.
Anticipating Possible Adverse Reactions from Chemotherapy Infusions
While rare, infusion reactions can result in a number of unexpected side effects that may have negative effects on a patient’s treatment.
Tumor Lysis Syndrome: What’s the Issue with Rasburicase Dosing?
Managing hyperuricemia is crucial to controlling TLS, and rasburicase catalyzes the enzymatic oxidation of uric acid into its inactive and soluble metabolite allantoin.
- Loading...
Loading...
Loading... 
Loading...